Sulfonylureas Market: Market Size & Forecast 2026

Sulfonylureas represent a well-established class of oral hypoglycemic agents that stimulate insulin secretion from pancreatic beta cells. They are subdivided into first-generation compounds, such as tolbutamide and chlorpropamide, and second-generation agents including glipizide, glyburide, and glimepiride. The market encompasses both branded and generic products sold across diverse healthcare systems worldwide.

• •Estimated at approximately $9.93 billion in 2025 with a compound annual growth rate near 3.26%
• •Classified as oral antidiabetic agents used primarily for type 2 diabetes management
• •Available in both first- and second-generation formulations

The market's expansion is closely linked to the growing global burden of type 2 diabetes, with major health organizations documenting rising prevalence across both developed and developing regions. Cost-effectiveness relative to newer antidiabetic drug classes sustains demand for sulfonylureas, especially in price-sensitive healthcare systems and among uninsured or underinsured patient populations. Generic availability further supports volume growth by keeping prices accessible.

• •Rising global prevalence of type 2 diabetes recorded by public health agencies such as the WHO and CDC
• •Lower unit cost compared to newer GLP-1 receptor agonists and SGLT2 inhibitors
• •Widespread generic availability driving volume consumption in emerging markets

Second-generation sulfonylureas dominate the market due to improved potency, dosing flexibility, and better tolerability profiles relative to first-generation compounds. North America and Europe hold significant market shares, supported by high diabetes prevalence and established generic distribution networks, while Asia-Pacific represents the fastest-growing region driven by rising disease burden and improving healthcare access.

• •Second-generation agents such as glimepiride, glipizide, and glyburide lead by sales value
• •North America and Europe account for the largest revenue shares
• •Asia-Pacific is a key growth region due to expanding diabetic populations and healthcare infrastructure development

What are the recent trends and outlook?

Sulfonylureas are expected to retain a stable, though gradually declining, position within the broader antidiabetic drug market as newer agents gain share in high-income countries. However, volume demand in emerging markets and cost-constrained health systems is likely to sustain overall market growth. The market is not tracked by official government statistical agencies; reliable sizing relies on commercial market research compilations.

• •Sustained volume growth in developing regions offsetting gradual substitution by newer drug classes in developed markets
• •Favorable positioning in national essential medicines lists supports continued formulary inclusion
• •Market size estimates are compiled by private research firms rather than official government statistical agencies